Drug Profile
Etoricoxib - Tremeau Pharmaceuticals
Alternative Names: Deuterium-enriched etoricoxib; TRM-359; TRM-362Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Tremeau Pharmaceuticals
- Class Antirheumatics; Non-opioid analgesics; Pyridines; Small molecules; Sulfones
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute pain
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Acute pain(In children) in USA (PO, Tablet)
- 25 Oct 2021 Etoricoxib is still in phase I trials for Acute pain in USA
- 25 Oct 2021 Tremeau Pharmaceuticals receives notice of allowance for composition of etoricoxib in the US